文献速递神经肿瘤

FET PET光子缺乏缺损在胶质瘤中的临床意义

Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.
PubMed 文献 · Neuro Oncol · 2019-01-01

该回顾性研究分析了100例FET PET阴性的胶质瘤患者,其中40例存在光子缺乏缺损。38%的光子缺乏胶质瘤为WHO III-IV级,且光子缺乏缺损与IDH突变型WHO II级弥漫性星形细胞瘤患者更短的无进展生存期相关(24 vs 51个月,P=0.027),多因素分析显示光子缺乏缺损是不良PFS的预测因素(P=0.009)。

要点

  • FET PET阴性胶质瘤中约40%存在光子缺乏缺损,其中38%为高级别胶质瘤。
  • 光子缺乏缺损组PFS显著短于 indifferent 摄取组(24 vs 51个月,P=0.027)。
  • 光子缺乏缺损是多因素分析中不良PFS的独立预测因素(P=0.009)。

核心结论

  • FET PET阴性扫描中的光子缺乏胶质瘤应更积极管理,因其具有更高风险为高级别胶质瘤且预后不良。

研究设计与样本

  • 回顾性识别神经病理确诊前FET PET阴性的胶质瘤患者,视觉评估为 indifferent 摄取或光子缺乏缺损,比较两组PFS。

主要发现

  • 光子缺乏胶质瘤的FET摄取显著低于健康脑组织(SUV 0.89±0.26 vs 1.08±0.23,P<0.001)和 indifferent 摄取胶质瘤(TBR 0.82±0.09 vs 0.96±0.13,P<0.001)。
  • IDH突变型WHO II级弥漫性星形细胞瘤中, indifferent 摄取组(n=25)PFS显著长于光子缺乏缺损组(n=11)(51 vs 24个月,P=0.027)。
  • 多因素生存分析显示光子缺乏缺损预测不良PFS(P=0.009)。

临床怎么用

  • 对于FET PET阴性但存在光子缺乏缺损的胶质瘤患者,应考虑更积极的临床管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET has a sensitivity of more than 90% to detect gliomas. In the remaining small fraction of gliomas without increased tracer uptake, some tumors even show photopenic defects whose clinical significance is unclear. METHODS: Glioma patients with a negative FET PET scan prior to neuropathological confirmation were identified retrospectively. Gliomas were rated visually as (i) having indifferent FET uptake or (ii) photopenic, if FET uptake was below background activity. FET uptake in the area of signal hyperintensity on the T2/fluid attenuated inversion recovery-weighted MRI was evaluated by mean standardized uptake value (SUV) and mean tumor-to-brain ratio (TBR). The progression-free survival (PFS) of photopenic gliomas was compared with that of gliomas with indifferent FET uptake. RESULTS: Of 100 FET-negative gliomas, 40 cases with photopenic defects were identified. Fifteen of these 40 cases (38%) had World Health Organization (WHO) grades III and IV gliomas. FET uptake in photopenic gliomas was significantly decreased compared with both the healthy-appearing brain tissue (SUV, 0.89 ± 0.26 vs 1.08 ± 0.23; P < 0.001) and gliomas with indifferent FET uptake (TBR, 0.82 ± 0.09 vs 0.96 ± 0.13; P < 0.001). Irrespective of the applied treatment, isocitrate dehydrogenase (IDH)-mutated WHO grade II diffuse astrocytoma patients with indifferent FET uptake (n = 25) had a significantly longer PFS than patients with IDH-mutated diffuse astrocytomas (WHO grade II) with photopenic defects (n = 11) (51 vs 24 mo; P = 0.027). The multivariate survival analysis indicated that photopenic defects predict an unfavorable PFS (P = 0.009). CONCLUSION: Photopenic gliomas in negative FET PET scans should be managed more actively, as they seem to have a higher risk of harboring a higher-grade glioma and an unfavorable outcome.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Galldiks N, Unterrainer M, Judov N, et al. Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients. Neuro Oncol. 2019. PMID: 31077276. doi:10.1093/neuonc/noz083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。